We are live on ! Find out more
VIR icon

Vir Biotechnology
VIR

213 hedge funds and large institutions have $558M invested in Vir Biotechnology in 2025 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 83 increasing their positions, 60 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more call options, than puts

Call options by funds: $1.9M | Put options by funds: $961K

38% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 60

12.13% more ownership

Funds ownership: 68% → 80.13% (+12%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

8% less capital invested

Capital invested by funds: $604M → $558M (-$46M)

9% less funds holding

Funds holding: 233 → 213 (-20)

45% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 42

Holders
213
Holders Change
-20
Holders Change %
-8.58%
% of All Funds
2.8%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
23
Increased
83
Reduced
60
Closed
42
Calls
$1.9M
Puts
$961K
Net Calls
+$936K
Net Calls Change
+$877K

Top Buyers

Rank Fund Capital Flow
1
AVM
Arch Venture Management
Illinois
+$69.3M
2
Citadel Advisors
Citadel Advisors
Florida
+$9.91M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.2M
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$3.67M
5
Nordea Investment Management
Nordea Investment Management
Sweden
+$3.03M

Top Sellers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
-$3.24M
2
WP
Woodline Partners
California
-$3.02M
3
State Street
State Street
Massachusetts
-$2.53M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$2.52M
5
BlackRock
BlackRock
New York
-$2.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
Prudential Financial
26
Prudential Financial
New Jersey
$3.08M -$313K -58,337 -9%
Millennium Management
27
Millennium Management
New York
$3.07M +$943K +175,914 +41%
Ensign Peak Advisors
28
Ensign Peak Advisors
Utah
$2.94M +$2.78M +519,107 +813%
BBA
29
Baker Bros. Advisors
New York
$2.73M – – –
APMC
30
Alta Partners Management Company
Wyoming
$2.57M +$42.9K +8,000 +2%
SCM
31
Sio Capital Management
New York
$2.41M +$25.4K +4,736 +1%
Barclays
32
Barclays
United Kingdom
$2.39M +$1.4M +262,035 +124%
Principal Financial Group
33
Principal Financial Group
Iowa
$2.31M -$1.6K -299 -0.1%
AQR Capital Management
34
AQR Capital Management
Connecticut
$2.26M +$968K +180,508 +67%
JP Morgan Chase
35
JP Morgan Chase
New York
$2.23M +$21.8K +4,069 +0.9%
Qube Research & Technologies (QRT)
36
Qube Research & Technologies (QRT)
United Kingdom
$2.22M +$801K +149,329 +51%
Bank of America
37
Bank of America
North Carolina
$2.15M -$241K -45,006 -10%
Citigroup
38
Citigroup
New York
$2.1M +$833K +155,433 +60%
Invesco
39
Invesco
Georgia
$2.04M -$3.9K -728 -0.2%
CCM
40
Catalio Capital Management
New York
$1.96M -$1.2M -223,305 -37%
Two Sigma Investments
41
Two Sigma Investments
New York
$1.86M +$520K +97,080 +36%
Allianz Asset Management
42
Allianz Asset Management
Germany
$1.65M +$102K +19,000 +6%
UBS Group
43
UBS Group
Switzerland
$1.59M -$870K -162,229 -34%
Two Sigma Advisers
44
Two Sigma Advisers
New York
$1.59M +$1.08M +202,200 +179%
Public Sector Pension Investment Board (PSP Investments)
45
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$1.58M +$116K +21,598 +7%
BFM
46
Boothbay Fund Management
New York
$1.54M – – –
SFI
47
Susquehanna Fundamental Investments
Pennsylvania
$1.51M -$169K -31,444 -9%
UBS AM
48
UBS AM
Illinois
$1.48M +$511K +95,320 +48%
American Century Companies
49
American Century Companies
Missouri
$1.38M +$86.3K +16,088 +6%
Corient Private Wealth
50
Corient Private Wealth
Florida
$1.31M +$5.18K +966 +0.4%
1
2
3 4 5

VIR Hedge Fund Activity: Q2 2025 in Review

213 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q2 2025, worth a combined $558M — down 7.6% from $604M a quarter earlier.

Sellers outnumbered buyers: 42 funds closed out of VIR and 23 opened new positions — a net loss of 19 holders — while 60 trimmed existing stakes and 83 added.

The largest buyer was Arch Venture Management, opening a new position worth an estimated $69.3M. The largest seller was Tang Capital Management, exiting entirely with an estimated $3.24M sold.

  • 213 institutional investors held Vir Biotechnology (VIR) as of Q2 2025, down from 233 in Q1 2025.
  • Funds reported $558M of Vir Biotechnology stock for Q2 2025, down 7.6% quarter-over-quarter.
  • 23 funds opened new Vir Biotechnology positions in Q2 2025 and 42 closed out, a net change of -19 holders.
  • The largest Vir Biotechnology buyer in Q2 2025 was Arch Venture Management, an estimated $69.3M added.
  • The largest Vir Biotechnology seller in Q2 2025 was Tang Capital Management, an estimated $3.24M sold.

Based on aggregated 13F filings for Q2 2025.